HAV Vaccines Limited

HAV Vaccines Limited is a United Kingdom-based biotechnology company headquartered in Newport Pagnell. The company is focused on developing novel immunologic treatments for Crohn's Disease, a chronic inflammatory bowel disease. Its core scientific premise is that Mycobacterium avium subsp. paratuberculosis (MAP), an intracellular pathogen, plays a key role in triggering and sustaining Crohn's Disease. HAV Vaccines is building a T cell immunotherapy platform designed to enable a patient's immune system to respond to this intracellular infection. The company describes its approach as addressing a gap in the current therapeutic landscape. Existing Crohn's Disease therapies primarily manage symptoms rather than target a possible causative agent. HAV Vaccines aims to create treatments that target MAP directly, with the ambition of delivering longer-lasting effects for a greater percentage of patients. Alongside its therapeutic candidates, the company is developing a companion diagnostic to advance understanding of MAP's role in the pathology of Crohn's Disease. Beyond Crohn's Disease, HAV Vaccines notes that MAP's role in autoimmune disease is a fast-growing area of research. While its immediate focus remains Crohn's Disease, the company believes its technology platform has the potential to address other conditions sharing autoimmune characteristics. The company actively seeks conversations with organizations that share its ambition to transform outcomes for patients with Crohn's Disease and other autoimmune diseases. As a privately held early-stage biotech, HAV Vaccines does not disclose public financial details, and its founding year and leadership are not specified in the available evidence. Its activities center on preclinical and clinical development of immunotherapies and diagnostics.

HAV Vaccines Limited is a biotechnology company based in Newport Pagnell, United Kingdom. It operates in the field of immunology and infectious disease, with a specific focus on Crohn's Disease. The company's founding year and early corporate history are not detailed in the available public evidence. The company's scientific foundation rests on the hypothesis that Mycobacterium avium subsp. paratuberculosis (MAP), an intracellular bacterium, is involved in triggering and sustaining Crohn's Disease. Building on this premise, HAV Vaccines has created a novel immunotherapeutic platform that targets MAP, aiming to give the patient's immune system the capability to respond to the intracellular infection. This platform is centered on T cell immunotherapies. In parallel with its therapeutic development, HAV Vaccines is developing a companion diagnostic. The company states that insights gained from this diagnostic are used to continuously advance its understanding of MAP's role in the pathology of Crohn's Disease. This dual approach—therapeutic plus diagnostic—reflects a precision-medicine strategy. HAV Vaccines positions its work as addressing a gap in the current therapeutic landscape. It notes that existing Crohn's Disease therapies manage symptoms, whereas its ambition is to create treatments that target the possible causative agent of the disease, with the goal of delivering longer-lasting effects for a greater percentage of patients. The company refers to its clinical trials as part of its development program, though specific trial phases, dates, or results are not provided in the available evidence. Looking ahead, HAV Vaccines has signaled interest in expanding beyond Crohn's Disease. It observes that MAP's role in autoimmune disease is a fast-growing area of research and that its technology has the potential to address other conditions sharing autoimmune characteristics. The company welcomes conversations with organizations that share its ambition to transform outcomes for patients with Crohn's Disease and other autoimmune diseases. As of the available evidence, the company remains privately held and active.

Early-stage biotech developing causative-agent-targeted immunotherapies for Crohn's Disease, differentiated from symptom-management therapies.

• T cell immunotherapy platform targeting MAP

  A novel immunotherapeutic platform that targets Mycobacterium avium subsp. paratuberculosis (MAP), designed to enable the patient's immune system to respond to the intracellular infection.

• Companion diagnostic for MAP

  A diagnostic being developed alongside the therapeutics to advance understanding of MAP's role in the pathology of Crohn's Disease.

1. 1HAV Vaccines — Developing new immunologic treatments for Crohn's Diseasehavvaccines.com
2. 2HAV Vaccines Limited (United Kingdom) - Wikidatawikidata.org